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Abstract  
 
Background/Aims: The von Hippel-Lindau (pVHL) protein functions as an E3 
ubiquitin ligase, controlling the stability of hypoxia inducible factor (HIF). 
Pre-induction of HIF-1α before pathological insult activates a self-defense mechanism 
and suppresses further aggravation of organ or cellular injury by ischemia. We 
investigated whether acute inactivation of the VHL gene might play a role in the 
response of mice to ischemic renal injury. Methods: We generated tamoxifen-inducible 
conditional VHL knockout (VHL-KO) mice to inactivate the VHL gene in an acute 
manner during renal ischemia-reperfusion injury (IRI) induced by bilateral clamping of 
kidney arteries. Renal IRI is characterized by renal dysfunction and tubular damage. 
Results: After the procedure of IRI, blood urea nitrogen (BUN) and creatinine (CRN) 
levels in control mice were significantly higher (BUN, 138.10±13.03 mg/dL; CRN, 
0.72±0.16 mg/dL) than in VHL-KO mice (BUN, 52.12±6.61 mg/dL; CRN, 0.24±0.04 
mg/dL; BUN: p<0.05; CRN: p<0.05). Histologically, tubular injury scores were higher 
in control mice than in VHL-KO mice (p<0.05). Conclusion: We suggest that the acute 
inactivation of the VHL gene contributes to protective effects of ischemic 
preconditioning in renal tubules of the mouse. 
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Introduction 
 
Hypoxia in the tubulointerstitium has been thought to play pivotal roles in the 
pathophysiology of acute renal failure. Ischemic acute renal failure is traditionally 
referred to as acute tubular injury [1]. Proliferation of affected tubular cells seems to be 
essential for timely recovery of tubules after acute renal damage and for subsequent 
functional recovery of the injured kidney [2]. The identification of the mechanisms 
responsible for the ischemic tubular damage is important not only for an understanding 
of the pathophysiology of ischemic injury but also for considering therapeutic strategies. 
Although the pathogenesis of human acute tubular injury is not fully understood, a 
number of animal studies have shown that several kinds of mediators can be involved in 
ischemia-reperfusion injury (IRI) in renal tubules [2-8]. 
Many processes of adaptation to hypoxia are mediated by hypoxia-inducible factor 
(HIF), which is a master regulator of genes transactivated by low oxygen tension. The 
level of HIF-1D protein, an oxygen-regulated component of HIF-1, is tightly regulated 
by von Hippel-Lindau (pVHL) protein. pVHL forms a complex with HIF-1D during 
normoxic conditions but not in ischemic hypoxia, and then rapidly induces 
ubiquitin-mediated degradation of HIF-1D [9,10]. Several published studies indicate 
that pre-induction of HIF-1D before pathological insult activates a self-defense 
mechanism and suppresses further aggravation of organ or cellular injury by ischemia 
[11-14]. One previous report concluded that pre-treatment with cobalt, which inhibits 
HIF-1D degradation and elevates its protein level, protected against subsequent renal 
tubular damage in rats with glomerular injury [14]. Furthermore, these authors have 
recently demonstrated a pivotal role for HIF-2D in IRI using HIF-2D knockdown mice 
[15]. HIF-2D is known as another target of pVHL, but plays different roles and 
possesses contrasting properties compared with HIF-1D in terms of expression levels 
and localization [16-18]. Although the roles of HIF-1D and HIF-2D were extensively 
investigated in these previous studies, especially under hypoxic conditions, the role of 
pVHL remains unclear in the progression of renal tubular damage induced by IRI. 
Given the potential importance of pVHL during ischemic conditions, we used VHL 
conditional knock out (VHL-KO) mice that expressed an inducible Cre recombinase 
transgene (CreERTM) [19] to delete the floxed VHL gene in an acute manner following 
tamoxifen induction.  We then investigated whether pre-inactivation of VHL would 
afford protection of renal tubules from injury during IRI.   
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Materials and Methods 
 
Generation of VHL conditional knockout (VHL-KO) mice 
Mice carrying the VHL conditional (floxed) allele were generated by Ma et al. [20], 
using Cre/lox site-specific recombination technology. To generate VHL conditional 
knockout (VHL-KO) mice in which VHL was inactivated in multiple tissues in an 
inducible manner, we crossed VHLf/f mice with VHLd/+ mice carrying the 
tamoxifen-inducible Cre recombinase transgene (VHLd/+/ CreERTM) [19] and selected 
for VHLf/d/ CreERTM offspring by PCR-based genotyping [21]. As already reported, Cre 
recombinase expression in this system is under the control of a human E-actin promoter. 
Therefore, Cre recombinase was expressed throughout the kidney as demonstrated by 
using ROSA26 reporter mice (Figure 1A). Based on the data reported by Hong and 
colleagues, we determined the least toxic concentration of tamoxifen that was still 
effective in inducing Cre recombination [21]. For our experiments, VHLf/d/ CreERTM 
mice were injected i.p. with tamoxifen in corn oil (0.36mg/g body weight) to activate 
Cre recombinase one week prior to renal IRI. Eight to fifteen-week-old male and female 
VHLf/d/ CreERTM mice (n=10) and littermate VHLf/+/ CreERTM control mice (n=6) were 
subjected to tamoxifen induction for these experiments. Mice were housed in a specific 
pathogen-free facility and were confirmed to be negative for common murine viral 
pathogens by routine sera analysis.  
 
Western Blot Analysis 
Protein from whole murine kidneys was prepared using Tissue Protein Extraction 
Reagent (T-PER) (Pierce Biotechnology, Rockford, Ill., USA). Western blot analysis 
was performed according to the methods in our previous study [22]. Kidney extracts 
were mixed with sample buffer, separated by electrophoresis on 15% SDS-PAGE gels 
and then transferred to PolyVinylidine DiFluoride (PVDF) membranes (Immobilon-P; 
Millipore, Bedford, Mass., USA). A rabbit polyclonal anti-VHL antibody (1:100; BD 
Biosciences, San Jose, CA, USA), a mouse monoclonal anti-HIF-1D antibody (1:500; 
Novus Biologicals, Inc., Littleton, CO, USA), a rabbit polyclonal anti-HIF-2D antibody 
(1:500; Novus Biologicals, Inc.), a rabbit polyclonal anti-erythropoietin antibody 
(1:500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), a mouse monoclonal 
anti-D-tubulin antibody (1:1000; Lab Vision, Fremont, CA, USA) and a mouse 
monoclonal anti-heme oxygenase (HO)-1 antibody (1:1000; Stressgen, Ann Arbor, MI, 
USA) were used with a horseradish peroxidase-conjugated secondary antibody 
(Promega, Madison, WI., USA). The ECL Plus Western blotting system (Amersham 
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Bioscience, Piscataway, N.J., USA) was used for detection. 
 
RT-PCR 
Total RNAs were isolated from mouse kidney using Trizol reagent (Invitrogen) 
according to the manufacturer's instruction. To remove genomic DNA contamination, 
RNAs were digested with DNase I for 1 hr at 37qC followed by heat denaturation at 
70qC for 20 min. Total RNAs (2.5 Pg) were primed with 100 ng random primers and 
reverse-transcribed by Superscript II reverse transcriptase (Invitrogen) at 42qC for 1 hr. 
The same reactions were performed without reverse transcriptase to generate negative 
controls. The following PCR primers were generated by using Primer 3 software [21]: 
VEGF forward, 5'- CAGGCTGCTGTAACGATGAA-3';  
VEGF reverse, 5'-TATGTGCTGGCTTTGGTGAG-3';  
E-actin forward, 5'-GACAGGATGCAGAAGGAGATTACTG-3';  
E-actin reverse, 5'-GCTGATCCACATCTGCTGGAA -3'.  
Quantitative RT-PCR was performed with SYBR-Green reagent (Applied Biosystems) 
with the ABI PRISM sequence detection system (Applied Biosystems) following the 
manufacturer's instruction. All reactions were run in triplicate using the E-actin gene 
as an internal control. 
 
Antibody Microarray Analysis 
In order to detect the proteins that were selectively expressed in the VHL-KO mouse 
kidney but not in control mouse kidney after tamoxifen induction, Panorama Cell 
Signaling Antibody Microarray kit (CSAA1, Sigma-Aldrich, St Louis, MO, USA) was 
used to detect a wide variety of proteins responsible for a broad range of biological 
functions, including apoptotic and cell cycle proteins. The antibody microarray was 
composed of 224 specific antibodies responsible for cell signaling, which were spotted 
in duplicate on nitrocellulose-coated glass slides. We prepared cell lysates from each 
kidney and the lysates were blotted according to manufacturer’s protocols. The 
complete list of arrayed antibodies can be found at the Sigma-Aldrich web site:  
http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/CSAA1. 
  
Induction of Renal Ischemia-Reperfusion Injury (IRI) 
Mice to be analyzed were anesthetized by i.p. injection of pentobarbiturate (4 mg/kg). 
Following abdominal incisions, the bilateral renal arteries were occluded at the proximal 
ends of the abdominal aorta with arterial clips for 30 min. After removal of the clips, the 
kidneys were checked for reperfusion. Twenty-four hours later, mice were sacrificed for 
 6 
further sampling and blood was collected for evaluation of renal function.  
 
Assessment of Renal Function 
Blood urea nitrogen (BUN) and creatinine (CRN) levels were measured for assessment 
of the renal function. BUN and CRN levels were analyzed by automated analysis 
(Hitachi 7350, Hitachi, Ibaraki, Japan) in our laboratory center. 
 
Histological Analysis 
To evaluate the kidney damage induced by renal IRI, histological analysis was 
performed. Four-micrometer-paraffin sections were stained with hematoxylin and eosin 
(H&E). On the basis of the method described by Leemans et al. [6], we evaluated the 
morphological changes in renal tubules. Tubular injury was scored by estimating the 
percentage of injured tubules in the outer medulla and corticomedullary junction that 
showed tubular dilation, tubular epithelial injury, debris accumulation, and cast 
formation as follows: 0 normal: 1 mild: 2 moderate: 3 severe. Twenty viewing fields 
randomly selected from the outer medulla and corticomedullary junction on each slide 
section were examined at x400 magnification. One slide per mouse kidney was 
evaluated. 
 
Immunohistochemical Analysis 
An immunohistochemical study was performed on paraffin sections of mouse kidneys 
using the Ventana automated immunohistochemistry system (Discovery TM, Ventana 
Medical system, Inc., Tucson, AZ, USA). VHL was identified with a polyclonal 
anti-VHL antibody, sc-5575 (1:150; Santa Cruz Biotechnology, Inc.). Antigen retrieval 
was performed for 60 min. in a preheated Dako Target Retrieval Solution (pH 6.0) using 
microwave treatment, followed by further steps including inhibition of intrinsic 
peroxidase, and blocking and reaction with a primary antibody.  
 
TUNEL (Terminal Deoxynucleotide Transferase dUTP Nick-End Labeling) staining 
TUNEL assay was performed to detect apoptosis in situ. Renal tissue sections were 
deparaffinized and rehydrated through three changes between xylene and graded alcohol, 
later washed in PBS for 5 min, and then incubated in 20μg/ml proteinase K for 15 min 
at room temperature. ApopTag Peroxidase In Situ Apoptosis Detection Kit (S7100, 
Chemicon International, Temecula, CA, USA) was used according to the manufacturer’s 
instructions. Endogenous peroxidase activity in the kidney sections was blocked by 
incubation for 5 min with 3% H2O2 in PBS, followed by incubation with equilibration 
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buffer for 10 sec. The sections were then incubated for 60 min at 37°C with terminal 
deoxynucleotidyl transferase (TdT) enzyme in reaction buffer. The reaction was finished 
by incubation with stopping buffer at room temperature. Sections were incubated with 
peroxidase-conjugated anti-digoxigenin antibody for 30 min at room temperature, and 
the reaction was developed with diaminobenzidine (DAB) substrate for 6 min at room 
temperature. Sections were counterstained with methyl green stain, dehydrated through 
a graded series of alcohol, and mounted for microscopy viewing. 
 
Statistical Analysis 
Data are reported as means ± standard error of the mean (SEM). An unpaired t test was 
used for paired samples and Student’s t test was used to compare the two groups. A p 
value of < 0.05 was considered statistically significant. 
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Results 
 
Expression level of VHL protein in VHL-KO mice 
To examine the distribution of Cre recombinase expression in the kidney for evaluating 
regions of VHL deletion, ROSA26 reporter mice were used. As shown in Figure 1A, Cre 
recombinase was expressed as purple staining throughout the kidneys of ROSA26 
CreERTM mice treated with tamoxifen (a), but not in the kidneys from tamoxifen-treated 
ROSA26 mice without the CreERTM transgene (b).  
To compare VHL protein expression in tamoxifen-treated VHL f/d/CreERTM (VHL-KO) 
mice and tamoxifen-treated VHL f/+/CreERTM (control) mice, we evaluated the levels of 
VHL protein in murine kidneys after tamoxifen induction by Western analysis (Fig. 1B). 
pVHL was detected in kidneys of control mice (left panel, Fig. 1B), but significantly 
reduced expression levels of VHL protein were detected in VHL-KO kidneys (right 
panel, Fig. 1B). In contrast to the VHL expression pattern, the protein levels of HIF-1D  
and HIF-2D were elevated in VHL-KO kidneys compared with control kidneys (Fig. 1B). 
These results demonstrated the effectiveness of the tamoxifen-inducible VHL 
conditional knockout mouse system, which causes VHL inactivation and stabilization of 
HIF-1D and HIF-2D protein, following tamoxifen injection. 
To further evaluate HIFD-inducible target genes, the protein levels of heme oxygenase 
(HO)-1 and erythropoietin (Epo), and gene expression levels of VEGF were compared. 
As demonstrated in Figure 1C, they were elevated in VHL-KO kidneys compared with 
control kidneys. 
 
BUN and CRN levels in VHL-KO and control mouse kidneys after IRI 
To assess whether VHL inactivation might play a role in renal protection during renal 
IRI, we subjected tamoxifen-injected VHL f/d/CreERTM (VHL-KO) and control mice to 
renal IRI by clamping the bilateral renal arteries. This procedure consisted of a 30 min 
ischemia followed by 24 h reperfusion. IRI significantly impaired renal function in 
control mice, as indicated by elevated serum BUN and CRN levels after 24 h 
reperfusion. The BUN and CRN levels in control mice (n=6) were 138.10 ± 13.03 
mg/dL and 0.72 ± 0.16 mg/dl, respectively. In contrast, serum BUN and CRN levels in 
VHL-KO mice (n=10) were 52.12 ± 6.61 mg/dl and 0.24 ± 0.04 mg/dl, respectively. 
There were significant differences in the levels of these renal function markers in 
VHL-KO mice compared with control mice (Fig. 2A, 2B). Compared to control mice, 
VHL-KO mice demonstrated a dramatic reduction in BUN and CRN levels (p < 0.05 for 
each comparison), suggesting that VHL inactivation had contributed to protection of 
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renal function following renal IRI. 
 
Histological analysis of the VHL-KO and control mouse kidneys after IRI  
Impairment of renal function, as assessed by BUN and CRN levels, was corroborated by 
histological evidence. By H&E staining, more severe tubular damage was detected in 
tamoxifen-treated control kidney sections with extensive proximal tubular injury 
including tubular dilatation and tubular epithelial degeneration with necrosis (Fig. 3A). 
In contrast, tamoxifen-injected VHL-KO mice subjected to renal IRI showed less 
proximal tubular injury with even milder tubular epithelial degeneration in the kidney 
sections (Fig. 3B). Proximal tubular damage was mainly observed from the outer 
medulla to the medullary ray of the cortex in control mice. No regions of necrotic debris 
or cast in the damaged tubules were detected in the sections from either VHL-KO or 
control kidneys. Compatible with the pathological changes in the control kidney, 
positive cells in TUNEL staining were detected in those regions, however, no TUNEL 
positive cells were detected in the VHL-KO kidney (Fig. 3E). Semi-quantitative analysis 
of tubular damage demonstrated that the levels of tubular injury scores were 
significantly higher in control mice (n=6) than in VHL-KO mice (n=10) (Fig. 3E, p < 
0.05). The scores in control mice and VHL-KO mice were 2.40 ± 0.08 and 0.90 ± 0.12, 
respectively. No pathological lesions of glomeruli and negligible numbers of infiltrated 
inflammatory cells were observed in VHL-KO and control kidney sections. 
 
Immunohistochemical analysis of the tamoxifen-injected VHL-KO and control 
mouse kidneys after IRI 
To further investigate the relationship between the localization of IRI-induced renal 
lesions and the distribution of VHL protein immunoreactivity in the kidneys, we 
performed immunohistochemical analysis of the VHL protein. The immunoreactivity of 
pVHL using anti-VHL antibody was mainly and strongly detected in the tubules of the 
tamoxifen-treated control mouse kidneys after renal IRI (Fig. 3C). In contrast, however, 
extremely weak immunoreactivity of pVHL was detected in the tubules of the 
tamoxifen-treated VHL-KO mice (Fig. 3D). We failed to detect pVHL immunoreactivity 
in glomeruli of either VHL-KO or control mice. TUNEL staining revealed positive 
apoptotic cells in the proximal tubules with the immunoreactivity of pVHL of the 
tamoxifen-treated control mouse kidneys after renal IRI (Fig.3E), while there were 
almost no positive cells in VHL-KO mice. 
 
Antibody microarray analysis of VHL-KO and control mouse kidneys after IRI 
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In order to investigate downstream signaling molecules that may contribute to renal 
protection from IRI as a consequence of VHL inactivation, we used an antibody 
microarray containing 224 cell signaling proteins to compare the relative expression 
levels of these proteins in VHL-KO and control kidneys following tamoxifen induction. 
Proteins showing a >1.5-fold difference in expression were considered significantly 
differentially expressed. We observed an increase in protein expression levels of 
anti-oxidant-like protein (Aop-1), NF-NB activating kinase (NAK), and Cdc7 kinase in 
VHL-KO compared with control kidneys. In contrast, a decrease in the expression of 
E2F1 was seen in VHL-KO kidneys relative to control kidneys (Fig. 4). 
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Discussion 
 
To date, there have been no representative studies in the nephrology field that 
extensively investigate the role of VHL protein in renal injuries induced by ischemia. In 
this study, using murine genetic approaches, we have used a conditional VHL-KO 
mouse model based on the tamoxifen-inducible CreERTM system to inactivate the VHL 
gene in an acute manner during ischemia caused by bilateral renal IRI.  
 Here we demonstrated that VHL-KO mice subjected to renal IRI had extremely mild 
renal tubular injury without significant increases in BUN and CRN, while severe tubular 
damage and significantly higher levels of BUN and CRN were detected in control 
kidneys. Our histological analysis and evaluation of renal function showed that VHL 
inactivation could ameliorate ischemia-reperfusion injury of mouse renal tubules.  
Matsumoto and colleagues reported that the most severe damage resulting from 
ischemic insult in a rat model extended from the outer medulla to the medullary ray of 
the cortex, suggesting that the proximal S3 segment and the thick ascending limb of the 
nephron are susceptible to ischemic injury [14]. Consistent with these findings, we 
frequently observed severe damage to the proximal tubules histologically in control 
mice. Furthermore, under normal conditions, VHL protein displays an expression 
pattern restricted to the proximal tubules of the kidney [23-25]. Our 
immunohistochemical analysis demonstrated that pVHL expression was detected 
strongly in the proximal tubules of the control kidneys, which coincided with the 
regions showing sustained moderate to severe injury after renal IRI. TUNEL staining of 
the tamoxifen-treated control mouse kidneys after renal IRI also revealed positive 
apoptotic cells in the proximal tubules with pVHL expression. In contrast, only weak 
immunoreactivity to VHL protein was found in the VHL-KO mouse kidney tubules that 
showed no damage.  
Although the mechanisms are not fully elucidated in the present study, taken together 
these findings suggest that reduced expression of VHL protein in renal proximal tubules 
of VHL-KO mice could inhibit the transition to acute tubular injury. Our antibody 
microarray data indicate that inactivation of VHL leads to upregulation of several 
proteins reported to be responsible for activation of cell survival and inhibition of 
apoptosis (i.e., Aop-1, NAK, Cdc7 kinase) suggesting that renal protection resulting 
from VHL inactivation may involve signaling through these pathways. Nonetheless, the 
finding that VHL-KO mice were significantly less susceptible to renal IRI compared 
with control mice suggests that acute inactivation of the VHL gene contributes 
protective effects against ischemic damage to renal tubules of VHL-KO mice.  
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Using this CreERTM system, in vivo deletion of the VHL gene leads to increases in 
VHL target proteins HIF-1D, as well as HIF-2D. Recently, it has been reported that 
HIF-2D is also involved in adaptation to hypoxic conditions [15-18]. Unlike HIF-1D, 
HIF-2D is known to be restricted in expression to only a few types of cells including 
endothelial cells, and it was reported that loss of HIF-2D resulted in functional 
disruption of the endothelium [15]. In contrast to that study, which used HIF-2D 
knockdown mice, our VHL conditional knockout mice kidneys showed increased 
expression of both HIF-1D and HIF-2D proteins. Therefore, it is suggested that 
elevation of those HIFD subunits partly contributes to attenuation of IRI. In addition, 
other than the HIFD-dependent processes, HIFD-independent effects of VHL must also 
be taken into account. Several lines of evidence support a role for VHL in maintenance 
of epithelial tissue architecture and extracellular matrix deposition [26-28], suggesting 
that VHL may also be involved in inhibition of the cell cycle and, consequently, loss of 
pVHL might activate cell proliferation signals. Therefore, in our study both 
HIFD-dependent and -independent processes might contribute to the final phenotype in 
VHL-KO mice. 
The present results also support our previous findings in another animal model, a rat 
model of glomerulonephritis, in which we demonstrated that VHL pre-induction by 
thrombin, a recently identified VHL inducer, aggravates glomerulonephritis [23]. 
Although the significance of VHL induction may vary in different animal models and 
cell types, our findings in the rat model suggest that VHL induction puts the kidney at a 
disadvantage, and may be a reflection of the results presented here. 
Several published reports have indicated that pre-induction of HIF-1D before 
pathological insult activates a self-defense mechanism and suppresses further 
aggravation of organ or cellular injury [11-13]. We have also previously shown that 
HIF-1D pre-induction by chemical hypoxia remarkably attenuated glomerulonephritis 
progression [24]. Furthermore, our recent studies demonstrated that HIF-1D was 
increased in VHL-null cells, even under normoxia, and directly enhanced apoptosis 
inhibitor (AI) gene expression, which suppresses mitochondrial function and reduces 
oxygen consumption [29]. Since the proximal tubules are rich in mitochondria for active 
transport and therefore oxygen demand is elevated, these regions with enhanced VHL 
expression levels are more susceptible to hypoxic events. Therefore, based on our recent 
study [29], it is suggested that VHL inactivation leads to HIFD stabilization, resulting in 
suppression of mitochondrial function and up-regulation of glucose metabolism. Our 
previous findings may suggest a possible mechanism, in the present study, by which 
VHL inactivation in the tamoxifen-inducible VHL-KO mice was protective against renal 
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tubular injury. Bearing in mind that pVHL plays an important role in regulating the 
HIFD protein levels, reduction of VHL protein levels appears to be a positive modulator 
of survival signals in renal tubular cells. However, our data does not exclude the 
possibility that prolonged ischemia in VHL-KO mice may lead to the activation of the 
HIF-1D-regulated growth factors, such as EPO, PDGF, and TGFD, that could override 
these protective effects against renal tubular injuries, since other reports show that a 
broad variety of inflammatory mediators and cytokines can regulate HIF-1D, which in 
turn negatively controls inflammatory processes, and such a mechanism might be 
involved in protection from IRI [30,31]. Further studies in VHL-KO mice are needed to 
define additional signal transduction pathways involved in renal tubular protection from 
the ischemic assault. 
In conclusion, we have shown that VHL-KO mice, in which acute VHL inactivation 
was induced by tamoxifen injection, were much less susceptible to renal IRI than 
control mice. This inducible VHL-inactivation system should prove useful as an in vivo 
model for evaluating drugs that can target HIF and HIF-regulated genes such as VEGF 
under ischemic conditions. Our present study has demonstrated a correlation between 
loss of VHL expression and protection against renal tubular injuries induced by 
ischemia.  Further study is needed to elucidate the mechanisms by which VHL 
inactivation initiates cell signaling leading to renal tubule protective effects during renal 
IRI.  
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Figure legends 
 
Figure 1 
VHL protein level is decreased following tamoxifen induction in VHL f/d/CreERTM 
(VHL-KO) mice with reciprocal elevation of HIF-1D .  
The distribution of Cre recombinase expression in the kidney was evaluated with 
ROSA26 reporter mice (A). After tamoxifen induction, Cre recombinase was expressed 
throughout the kidney in ROSA26 CreERTM mice (a), but not in ROSA26 mice lacking 
the CreERTM transgene (b). Each lane represents a protein extract from a 
tamoxifen-treated VHL-KO mouse kidney, in which Cre recombinase was induced, or a 
tamoxifen-treated control mouse kidney. D-tubulin is used as a loading control. VHL 
protein expression is decreased in tamoxifen-induced VHL-KO kidneys, with elevation 
of HIF-1D, HIF-2D (B), heme oxygenase (HO)-1, and erythropoietin (C) protein levels. 
Furthermore VEGF gene expression evaluated by RT-PCR is also increased (C). 
Representative data are shown (n=2 per group for Western blot analysis; n= 3 per group 
for RT-PCR). 
 
Figure 2 
VHL inactivation causes protection of kidney function during renal IRI. 
BUN (A) and creatinine (B) levels in tamoxifen-injected VHL-KO mice (n=10) are 
significantly lower than those of control mice (n=6; p< 0.05) after renal IRI. 
 
Figure 3 
VHL inactivation reduces tubular damage caused by renal IRI.  
H&E staining of kidney sections show renal tubules from control (A) and VHL-KO (B) 
mice, 24 h after reperfusion. Severe tubular damage is observed in control mice (A), 
compared with VHL-KO mice (B). Immunohistochemical staining shows less VHL 
protein expression in the renal tubules in VHL-KO mice (D) compared with control 
mice (C). The tubular injury score in VHL-KO mice (n=10) is lower than in control mice 
(n=6; p<0.05), compatible with fewer TUNEL positive cells in VHL-KO mice compared 
with control mice (E).  
 
Figure 4 
Antibody microarray analysis of VHL-KO mice. 
Representative data showing down-regulated and up-regulated protein expression levels 
in VHL-KO mice compared with control mice. 
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